Advertisement – Charles Stanley mid banner
Advertisement: EBCam mid banner
Advertisement: Cambridge Network mid banner
Advertisement: Kao Data Centre mid banner
Advertisement: Hewitsons mid banner
CBM light up lives mid banner advert
Advertisement: Mogrify mid banner
Advertisement: Howard Group mid banner
Barr Ellison Solicitors – commercial property
Advertisement: TTP
Advertisement: RSM
ARM Innovation Hub
Advertisement: EY Mid banner
Advertisement: CJBS mid banner
Advertisement: Wild Knight Vodka
Mid banner advertisement: BDO
Advertisement: S-Tech mid banner 3
Advertisement: Simpsons Creative
1 September, 2020 - 10:42 By Tony Quested

Mursla raising cash to advance cancer innovation technology

Mursla, a Cambridge University liquid biopsy spin-out, has raised £410K from the UK Government’s Future Fund and existing investors plus a £40K COVID-19 grant from the Cambridgeshire Capital Grant Scheme.

It is tilting at raising bigger money from a Series A after relocating from the Cavendish Laboratory to Cambridge Science Park.

The new funding will enable Mursla to finalise its work on its novel exosome-based liquid biopsy platform, ExoPheno, to show how the platform can detect cancer signatures in plasma from solid tumours via exosomes.

Exosomes are heterogeneous vesicles naturally released by all cells during their lives, especially tumour cells, and usually carry biologically active molecules that can deliver their messages to local or distant targets.

A cancer liquid biopsy is a test undertaken on a blood sample to look for tumour information, including from nucleic acids or proteins, that is circulating in the blood. 

Much less invasive and heterogeneous than traditional biopsies, which require local anaesthesia and often cause discomfort to the patient, this simple blood draw could routinely offer life-saving early cancer detection or help monitor tumours during and after treatments.

The liquid biopsy space has seen tremendous progress over the last five years, as evidenced by the first FDA approval for cancer liquid biopsy via nucleic acid sequencing as a companion diagnostic in August this year. 

However, due to its lack of sensitivity, this route failed to demonstrate game-changing early cancer detection. Mursla’s novel approach could provide the solution to this problem.

The business has also just relocated from its roots at the Cavendish Laboratory at the University of Cambridge to its own laboratory and office space at the Cambridge Science Park.

Pierre Arsène, founder & CEO, Mursla said: “The additional funding is a mark of confidence in our strategy from both the UK government and our existing investors in this currently challenging environment. 

“It has allowed us to make up for lost time during lockdown and expedited our move to fully equipped lab space at Cambridge Science Park, which has been an extremely positive step forward.

“Our next goal is to find VC partners to help us scale our assays and validate our own exosome-based biomarker panel for liver cancer detection.”

As Mursla approaches significant milestones in the development of its platform, the company aims to raise its Series-A by the end of this year.

Newsletter Subscription

Stay informed of the latest news and features